Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Surface Oncology, Inc.    SURF

SURFACE ONCOLOGY, INC.

(SURF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Surface Oncology : to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

share with twitter share with LinkedIn share with facebook
08/05/2020 | 11:59am EDT

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, will present at the upcoming Wedbush PacGrow Healthcare Virtual Conference on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging preclinical pipeline, including SRF813 (targeting CD112R, also known as PVRIG).

The presentation will take place virtually on Tuesday, August 11, 2020 at 10:55 a.m. EDT. The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website: investors.surfaceoncology.com.

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397


Surface Logo New Version-color.png

Source: Surface Oncology, Inc.

2020 GlobeNewswire, Inc., source Press Releases


share with twitter share with LinkedIn share with facebook
All news about SURFACE ONCOLOGY, INC.
09/16SURFACE ONCOLOGY : to Participate in the Oppenheimer Fall Healthcare Life Scienc..
AQ
09/16Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Scien..
GL
09/11SURFACE ONCOLOGY : to Participate in the H.C. Wainwright Global Healthcare Confe..
AQ
09/11Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conf..
GL
09/09SURFACE ONCOLOGY : to Present at the Baird Global Healthcare Conference
AQ
09/09Surface Oncology to Present at the Baird Global Healthcare Conference
GL
08/11Surface Oncology Reports Financial Results and Corporate Highlights for Secon..
GL
08/11SURFACE ONCOLOGY : Management's Discussion and Analysis of Financial Condition a..
AQ
08/11SURFACE ONCOLOGY, INC. : Results of Operations and Financial Condition, Financia..
AQ
08/05SURFACE ONCOLOGY : to Present at the 2020 Wedbush PacGrow Healthcare Virtual Con..
AQ
More news
Financials (USD)
Sales 2020 38,6 M - -
Net income 2020 -25,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -13,1x
Yield 2020 -
Capitalization 382 M 382 M -
Capi. / Sales 2020 9,90x
Capi. / Sales 2021 102x
Nbr of Employees 49
Free-Float 98,3%
Chart SURFACE ONCOLOGY, INC.
Duration : Period :
Surface Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURFACE ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 10,50 $
Last Close Price 9,57 $
Spread / Highest target 25,4%
Spread / Average Target 9,72%
Spread / Lowest Target -5,96%
EPS Revisions
Managers
NameTitle
J. Jeffrey Goater President, Chief Executive Officer & Director
Daniel S. Lynch Executive Chairman
Jessica Fees Treasurer, Chief Financial & Accounting officer
Vito J. Palombella Chief Scientific Officer
Robert W. Ross Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SURFACE ONCOLOGY, INC.409.04%382
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097